iRhythm Technologies, Inc.

Informe acción NasdaqGS:IRTC

Capitalización de mercado: US$3.5b

iRhythm Technologies Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de iRhythm Technologies han disminuido a una tasa media anual de -21.7%, mientras que en la industria Medical Equipment los beneficios crecieron en un 13.5% anualmente. Los ingresos han ido creciendo a una tasa media de 21.9% al año.

Información clave

-21.7%

Tasa de crecimiento de los beneficios

-17.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment 8.9%
Tasa de crecimiento de los ingresos21.9%
Rentabilidad financiera-58.7%
Margen neto-25.0%
Próxima actualización de resultados02 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Business Is Trailing The Industry But Its Shares Aren't

Mar 25
iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Business Is Trailing The Industry But Its Shares Aren't

Here's What Analysts Are Forecasting For iRhythm Technologies, Inc. (NASDAQ:IRTC) After Its Annual Results

Feb 25
Here's What Analysts Are Forecasting For iRhythm Technologies, Inc. (NASDAQ:IRTC) After Its Annual Results

iRhythm Technologies (NASDAQ:IRTC) Has Debt But No Earnings; Should You Worry?

Feb 02
iRhythm Technologies (NASDAQ:IRTC) Has Debt But No Earnings; Should You Worry?

iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Could Be 30% Below Their Intrinsic Value Estimate

Dec 20
iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Could Be 30% Below Their Intrinsic Value Estimate

iRhythm Technologies, Inc. (NASDAQ:IRTC) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Dec 20
iRhythm Technologies, Inc. (NASDAQ:IRTC) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Is Now An Opportune Moment To Examine iRhythm Technologies, Inc. (NASDAQ:IRTC)?

Dec 02
Is Now An Opportune Moment To Examine iRhythm Technologies, Inc. (NASDAQ:IRTC)?

Health Check: How Prudently Does iRhythm Technologies (NASDAQ:IRTC) Use Debt?

Sep 20
Health Check: How Prudently Does iRhythm Technologies (NASDAQ:IRTC) Use Debt?

iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Could Be 25% Below Their Intrinsic Value Estimate

Aug 30
iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Could Be 25% Below Their Intrinsic Value Estimate

When Should You Buy iRhythm Technologies, Inc. (NASDAQ:IRTC)?

Jul 04
When Should You Buy iRhythm Technologies, Inc. (NASDAQ:IRTC)?

Is iRhythm Technologies (NASDAQ:IRTC) Using Debt In A Risky Way?

Jun 16
Is iRhythm Technologies (NASDAQ:IRTC) Using Debt In A Risky Way?

Estimating The Intrinsic Value Of iRhythm Technologies, Inc. (NASDAQ:IRTC)

May 26
Estimating The Intrinsic Value Of iRhythm Technologies, Inc. (NASDAQ:IRTC)

iRhythm Technologies, Inc.'s (NASDAQ:IRTC) P/S Is On The Mark

May 08
iRhythm Technologies, Inc.'s (NASDAQ:IRTC) P/S Is On The Mark

What Does iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Share Price Indicate?

Mar 27
What Does iRhythm Technologies, Inc.'s (NASDAQ:IRTC) Share Price Indicate?

Is iRhythm Technologies (NASDAQ:IRTC) Using Debt Sensibly?

Feb 25
Is iRhythm Technologies (NASDAQ:IRTC) Using Debt Sensibly?

Health Check: How Prudently Does iRhythm Technologies (NASDAQ:IRTC) Use Debt?

Nov 24
Health Check: How Prudently Does iRhythm Technologies (NASDAQ:IRTC) Use Debt?

iRhythm falls after reaffirming 2022 guidance

Sep 21

iRhythm: Fairly Priced At Current Multiples, No Need To Size Up

Sep 02

Is iRhythm Technologies (NASDAQ:IRTC) Using Debt In A Risky Way?

Aug 18
Is iRhythm Technologies (NASDAQ:IRTC) Using Debt In A Risky Way?

iRhythm Technologies Q2 results beat estimates, co raises FY 2022 revenue guidance

Aug 04

iRhythm Technologies provides FY22 prelims, commercial chief resigns

Jul 19

iRhythm: Reimbursement Overhang Squashed, Bull Thesis Back Intact

Jun 08

Is iRhythm Technologies (NASDAQ:IRTC) A Risky Investment?

Apr 14
Is iRhythm Technologies (NASDAQ:IRTC) A Risky Investment?

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero iRhythm Technologies. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqGS:IRTC Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 23493-12337060
30 Sep 23473-10535658
30 Jun 23452-9935453
31 Mar 23430-10534451
31 Dec 22411-11631747
30 Sep 22380-12830446
30 Jun 22362-13129743
31 Mar 22341-12427841
31 Dec 21323-10127539
30 Sep 21320-7926038
30 Jun 21306-5923838
31 Mar 21276-6321941
31 Dec 20265-4419741
30 Sep 20245-5119539
30 Jun 20228-6519144
31 Mar 20230-5519039
31 Dec 19215-5518037
30 Sep 19197-5416335
30 Jun 19181-4515027
31 Mar 19165-4814324
31 Dec 18147-5013321
30 Sep 18134-4512318
30 Jun 18120-4211117
31 Mar 18108-359615
31 Dec 1799-308513
30 Sep 1789-257311
30 Jun 1781-22659
31 Mar 1773-20578
31 Dec 1664-21527
30 Sep 1656-22487
30 Jun 1649-24457
31 Mar 1641-24406
31 Dec 1536-23376
30 Sep 1532-19316
31 Dec 1422-16206
31 Dec 1315-14144

Ingresos de calidad: IRTC actualmente no es rentable.

Margen de beneficios creciente: IRTC actualmente no es rentable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: IRTC no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 21.7% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de IRTC en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: IRTC no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Medical Equipment (3.3%).


Rentabilidad financiera

Alta ROE: IRTC tiene una rentabilidad financiera negativa (-58.74%), ya que actualmente no es rentable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target